“…12 Even though a few preliminary mechanistic studies regarding the bioactivities of these alkaloids have been reported, the exact targets for the majority of these bioactivities have yet to be identified. Notably, Chen and co-workers reported that securinine derivatives effectively inhibit DNA topoisomerase I (Topo I), 13,14 the target of the FDA-approved ADC drug Enhertu (trastuzumab deruxtecan). 15 From a structural perspective, basic monomeric securinega alkaloids are characterized by a fused tetracyclic core with a conjugated ester moiety and a piperidine heterocycle.…”